Boan Bio (06955.HK): The new indication of Bolojia injection solution has been approved in China for the treatment of solid tumor bone metastasis and multiple myeloma.

The Zhongtong Financial APP news, Boan Biology (06955.HK) announced that the China National Medical Products Administration has approved a supplementary application for the additional indications of Bolorgen (disulfonate monoclonal antibody injection 120mg), it is used for the treatment of solid tumor bone metastasis or multiple myeloma patients, to delay or reduce the risk of bone-related events (pathological fractures, spinal cord compression, bone radiation therapy or bone surgery) occurring.